PCO371

1613373-33-3

CAS-Nr.: 1613373-33-3

Englisch Name:: PCO371

Synonyma:: PCO371;CPD2050;PCO371,PCO 371,inhibit,Inhibitor,THR,PCO-371,Thyroid Hormone Receptor;1-[3,5-Dimethyl-4-[2-[[4-oxo-2-[4-(trifluoromethoxy)phenyl]-1,3,8-triazaspiro[4.5]dec-1-en-8-yl]sulfonyl]ethyl]phenyl]-5,5-dimethylimidazolidine-2,4-dione;1-[3,5-Dimethyl-4-[2-[[4-oxo-2-[4-(trifluoromethoxy)phenyl]-1,3,8-triazaspiro[4.5]dec-1-en-8-yl]sulfonyl]ethyl]phenyl]-5,5-dimethyl-2,4-imidazolidinedione;2,4-Imidazolidinedione, 1-[3,5-dimethyl-4-[2-[[4-oxo-2-[4-(trifluoromethoxy)phenyl]-1,3,8-triazaspiro[4.5]dec-1-en-8-yl]sulfonyl]ethyl]phenyl]-5,5-dimethyl-

CBNumber:: CB03355936

Summenformel:: C29H32F3N5O6S

Molgewicht:: 635.65

MOL-Datei:: 1613373-33-3.mol

Request For Quotation

Eigenschaften Sicherheit Verwendungswort Produktionsfirma 43

PCO371 Eigenschaften

Dichte: 1.47±0.1 g/cm3(Predicted)

storage temp.: Store at -20°C

Löslichkeit: DMSO: 125 mg/mL (196.65 mM)

Aggregatzustand: Solid

pka: 8.39±0.10(Predicted)

Farbe: White to off-white

InChIKey: LDZJFVOUPUFOHX-UHFFFAOYSA-N

SMILES: C1(=O)N(C2=CC(C)=C(CCS(N3CCC4(N=C(C5=CC=C(OC(F)(F)F)C=C5)NC4=O)CC3)(=O)=O)C(C)=C2)C(C)(C)C(=O)N1

Sicherheit

PCO371 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

PCO371 is a novel, orally active small molecule that acts as a full agonist of PTHR1. PCO371 does not affect the PTH type 2 receptor (PTHR2), and analysis using PTHR1-PTHR2 chimeric receptors indicated that Proline 415 of PTHR1 is critical for PCO371-mediated PTHR1 activation[1].

Verwenden

PCO371 is a non-peptide chemical parathyroid hormone receptor 1 (PTHR1) agonist that exhibits PTH-mimetic activity in vivo via oral administration. PTH1R is a class B1 G protein-coupled receptor (GPCR) and a major regulator of mineral ion homeostasis and bone metabolism. PTH1R responds to ligands for parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) and activates Gs, Gq and β-arrestins. Natural and modified forms of these ligands induce substantial anabolic bone formation and are used in the clinical treatment of osteoporosis. PCO371 is used in the treatment of patients with hypoparathyroidism.

PCO371 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

PCO371 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 43)Lieferanten

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Wuhan Jingkang en Biomedical Technology Co., Ltd	+8613720134139	orders@jknbiochem.com	China	5225	58
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	19892	58
HANGZHOU CLAP TECHNOLOGY CO.,LTD	86-571-88216897,88216896 13588875226	sales@hzclap.com	CHINA	6313	58
Nantong HI-FUTURE Biology Co., Ltd.	+undefined18051384581	sales@chemhifuture.com	China	3136	58
Wuhan Topule Biopharmaceutical Co., Ltd	+8618327326525	masar@topule.com	China	8474	58
LEAPCHEM CO., LTD.	+86-852-30606658	market18@leapchem.com	China	43348	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 13720134139	orders@jknbiochem.com	China	5608	58
ShangHai Caerulum Pharma Discovery Co., Ltd.	18149758185	sales-cpd@caerulumpharma.com	China	3466	58
Shanghai Rechem science Co., Ltd.	21-31433387 15618786686	sales@rechemscience.com	China	2944	58
Shenzhen SUNGENING Bio-Medical Co., Ltd.	0755-28967200 13631290199	wxf@sungening.com	China	9592	60

PCO371
CPD2050
2,4-Imidazolidinedione, 1-[3,5-dimethyl-4-[2-[[4-oxo-2-[4-(trifluoromethoxy)phenyl]-1,3,8-triazaspiro[4.5]dec-1-en-8-yl]sulfonyl]ethyl]phenyl]-5,5-dimethyl-
1-[3,5-Dimethyl-4-[2-[[4-oxo-2-[4-(trifluoromethoxy)phenyl]-1,3,8-triazaspiro[4.5]dec-1-en-8-yl]sulfonyl]ethyl]phenyl]-5,5-dimethyl-2,4-imidazolidinedione
PCO371,PCO 371,inhibit,Inhibitor,THR,PCO-371,Thyroid Hormone Receptor
1-[3,5-Dimethyl-4-[2-[[4-oxo-2-[4-(trifluoromethoxy)phenyl]-1,3,8-triazaspiro[4.5]dec-1-en-8-yl]sulfonyl]ethyl]phenyl]-5,5-dimethylimidazolidine-2,4-dione
1613373-33-3
C29H32F3N5O6S